Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes
JCI Insight · 2026
DOI: 10.1172/jci.insight.199050 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Ivan I Golodnikov und 17 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Centre, Moscow, Russia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Transcriptome, Latent Autoimmune Diabetes in Adults. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Autoimmune diabetes encompasses rapidly progressive type 1 diabetes mellitus (T1D) and indolent latent autoimmune diabetes in adults (LADA), which represent distinct inflammatory set points along a shared autoimmune spectrum. Yet, the immunological mechanisms that determine these divergent inflammatory states remain unresolved. We performed single-cell RNA sequencing with paired T and B cell receptor profiling on over 400,000 PBMCs from patients with LADA, newly diagnosed T1D, and individuals acting as healthy controls. PBMC composition was comparable across cohorts, indicating that qualitative rather than quantitative immune differences underlie disease heterogeneity. In T1D, pan-lineage activation of NF-κB, EGFR, MAPK, and hypoxia pathways, coupled with a TNF-centered communication hub, enhanced MHC signaling, disrupted adhesion, and promoted systemic inflammation. LADA, by contrast, exhibited global suppression of NF-κB/EGFR activity, retention of moderate JAK/STAT tone, reinforced NK cell inhibitory checkpoints via HLA-C–KIR2DL3/3DL1 interaction, and stabilized CD8 + T cell synapses through HLA-C–CD8 binding, collectively restraining effector activation. Single-cell V(D)J analysis revealed multiclonal, patient-unique adaptive repertoires, emphasizing the primacy of signaling context over receptor convergence. These findings define autoimmune diabetes as an inflammatory-inhibitory set-point continuum, positioning the NF-κB/EGFR–JAK/STAT gradient and HLA-C–KIR axis as potential therapeutic targets to preserve residual β cell function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Research Centre, Moscow, Russia.
- Medical Research and Educational Institute, Lomonosov Moscow State University, Moscow, Russia.
- Federal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, Moscow, Russia.
Förderung
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Golodnikov, I. I., Podshivalova, E. S., Chechekhin, V. I., Zubritskiy, A. V., Matrosova, A. A., Sergeev, N. A., Samsonova, M. D., Dvoryanchikov, Y. V., Nikonova, T. V., Bondarenko, E. V., Loguinova, M. Y., Medvedeva, Y. A., Laptev, D. N., Khusainova, R. I., Minniakhmetov, I. R., Shestakova, M. V., Mokrysheva, N. G., & Dedov, I. I. (2026). Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes. JCI Insight. https://doi.org/10.1172/jci.insight.199050
Vancouver
Golodnikov II, Podshivalova ES, Chechekhin VI, Zubritskiy AV, Matrosova AA, Sergeev NA, et al. Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes. JCI Insight. 2026. doi:10.1172/jci.insight.199050
BibTeX
@article{Golodnikov2026,
author = {Golodnikov, Ivan I and Podshivalova, Elizaveta S and Chechekhin, Vadim I and Zubritskiy, Anatoliy V and Matrosova, Alina A and Sergeev, Nikita A and Samsonova, Margarita D and Dvoryanchikov, Yaroslav V and Nikonova, Tatiana V and Bondarenko, Ekaterina V and Loguinova, Marina Yu and Medvedeva, Yulia A and Laptev, Dmitry N and Khusainova, Rita I and Minniakhmetov, Ildar R and Shestakova, Marina V and Mokrysheva, Natalia G and Dedov, Ivan I},
title = {Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.199050}
}
EUVIMED